🟢 Outlook Therapeutics is trading 5.3% up in pre-market with no new company-specific announcement identified

Outlook Therapeutics is trading 5.33% up now at $0.67 in pre-market, though no new company-specific announcement was identified for August 26, 2026.

• Latest company releases were the August 14 quarterly update and August 12 financing announcement; both are established rather than overnight catalysts.
• The FDA approval was announced July 24 and is also an established catalyst; broader futures are mixed.